Florida Access and Licensing Standards PlexusDx partners exclusively with licensed 503A compounding pharmacies registered with Florida's Department of Business and Professional Regulation
These platforms primarily offered compounded GLP-1 products, which are facing increasing FDA regulatory scrutiny in 2026
By activating GLP-1, GIP, and glucagon receptors simultaneously, it addresses appetite, blood sugar regulation, and energy expenditure in a way that single-pathway treatments simply cannot
Follow-up appointments should assess: Weight loss progress and metabolic improvements Tolerability and side effect management Adherence to medication and lifestyle changes Nutritional adequacy and prevention of deficiencies Any new or worsening digestive symptoms Renal function if dehydration is a concern Patients should maintain open communication with their healthcare team about any concerns
This article provides a research-only overview of dosing ranges observed in studies, summaries of administration methods used in experimental settings, and patterns commonly referenced in scientific and community discussions